Somatostatin receptor scintigraphy findings in a patient with metastatic gastrinoma and MEN 1 syndrome

Nöroendokrin tümörlerde karaciğer metastazı sıklıkla görülmekte ve prognozu kötüleştirmektedir. Somatostatin reseptör sintigrafisi (SRS) gastrinoma gibi somatostatin reseptörü pozitif lezyonları tanımlamada oldukça değerli bir yöntemdir. Bu olgu sunumunda, karaciğerde nöroendokrin tümör metastazları saptanan bir hastada primer tümörün SRS ile yerinin belirlenmesinin ve hastalığın yaygınlığının değerlendirilmesinin önemi vurgulandı. 45 yaşında erkek hastada karaciğerde nöroendokrin tümöre ait multipl metastaz saptandı. Somatostatin reseptör sintigrafisinde karaciğerde çoklu yoğun ve sağ üst kadranda duodenum veya pankreasa uyan alanda fokal radyofarmasötik tutulumları izlendi. Yüksek gastrin seviyesi ile gastrinoma tanısı konuldu. (MIRT 2011;20:117-120)

Metastatik gastrinomalı ve MEN 1 sendromlu hastada somatostatin reseptör sintigrafisi bulguları

Liver metastases from neuroendocrine tumours frequently occur and significantly worsen their prognosis. Somatostatin receptor scintigraphy (SRS) is a valuable method for the detection of somatostatin receptor-positive lesions like gastrinoma. In this case report, the importance of SRS to localize the primary tumor and the spread of disease is emphasized in a patient with neuroendocrine liver metastases. A 45-year-old man was admitted to hospital with multiple liver metastasis of neuroendocrine carcinoma. Somatostatin receptor scintigraphy showed multiple intense radiotracer uptakes in the liver and a focal tracer uptake at the right side of the upper abdominal region corresponding to duodenum or pancreas. Elevated serum gastrin levels confirmed the gastrinoma diagnosis. (MIRT 2011;20:117-120)

Kaynakça

1. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 2010;12:361-379.

2. Marini F, Falchetti A, Monte DF, Sala CS, Gozzini A, Luzi E, Brandi ML. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006;1:1-38.

3. Yeo CJ. Neoplasms of endocrine pancreas. In: Greenfield LJ, Mulholland MW, Oldham GB, et al. eds. Essentials of surgery: scientific principles and practice, Lippincott-Raven Publishers, Philadelphia, 1997, page 258-262.

4. Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Braunwald E, Fauci A, Kasper D, et al, eds. Harrison’s Principles of Internal Medicine, 15th Edition. McGraw- Hill Companies. 2001, Volume 1, page 593-604.

5. Entok E, Ak I, Bekis R, Bozkurt MF, Burak Z, Dede Z, Degirmenci B, Narin Y, Tamgaç F, Töres G, Yildiz A, Yilmaz M, Yüksel D, Yüksel M, Vardareli E. Procedure Guideline For Somatostanin Receptor Scintigraphy. Turk J Nucl Med 2001;10(Supp):109-114.

6. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, Boese-Landgraf J, Neuhaus P , Ziske C, Mölling K , Riecken EO , Reubi JC , Wiedenmann B. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-39.

7. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282.

8. Langer P, Kann PH, Fendrich V, Richter G, Diehl S, Rothmund M, Bartsch DK. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004;28:1317-1322.

9. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with somatostatin receptor PET radioligand (68) Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757.

10. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R. Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors: A Single-Centre Retrospective Study. Clin Nucl Med 2010;35:321-328.

11. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26-34.

12. Klose KJ, Heverhagen JT. Localisation and staging of gastrin producing tumours using cross-sectional imaging modalities. Wien Klin Wochenschr 2007;119:588-592.

13. Gao C, Fu X, Pan Y, Li Q. Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg 2010;27:197-204.

14. Falconi M, Bettini R, Boninsegna L, Crippa S, Butturini G, Pederzoli P. Surgical Strategy in the Treatment of Pancreatic Neuroendocrine Tumors. JOP 2006;7:150-156.

Kaynak Göster

Molecular Imaging and Radionuclide Therapy
  • ISSN: 2146-1414
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1992

1.3b474